Brivanib alaninate: VEGFR/FGFR inhibitor oncolytic

Drugs of the Future

Volumn 34, Issue 11, 2009, Pages 881-895

  Huynh, H ^a   Fargnoli, J ^b  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; BRIVANIB; BRIVANIB ALANINATE; CAPECITABINE; CETUXIMAB; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DOXORUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR; IXABEPILONE; PROTEIN INHIBITOR; SORAFENIB; SUNITINIB; VASCULOTROPIN RECEPTOR;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTHENIA; BLEEDING; BRAIN DISEASE; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL STUDY; CLINICAL TRIAL; COLORECTAL CANCER; DEHYDRATION; DERMATITIS; DIARRHEA; DIGESTIVE SYSTEM CANCER; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG TOLERABILITY; FATIGUE; FEVER; GAIT DISORDER; GASTRODUODENAL MALIGNANCY; GROWTH INHIBITION; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; IN VIVO STUDY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG EMBOLISM; MENTAL DISEASE; NAUSEA; NONHUMAN; OPEN STUDY; REVIEW; SIDE EFFECT; SOLID TUMOR; SYNTHESIS; THROMBOCYTE COUNT; THROMBOEMBOLISM; TUMOR XENOGRAFT; VOMITING; WOUND HEALING IMPAIRMENT;

EID: 77950597027     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2009.034.11.1436615     Document Type: Review

References (84)

1. Bhide, R.S., Cai, Z.W., Zhang, Y.Z. et al. Discovery and preclinical studies of (R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f] [1,2,4]triozin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VECFR-2 inhibitor. J Med Chem 2006, 49(7): 2143-2146
2. Cai, Z.-W., Qian, L., Bhide, R., Barbosa, A. (Bristol-Myers Squibb Co.). Novel inhibitors of kinases. EP 1434290, JP 2005538989, US 2004072832, US 6869952, WO 2004009784.
3. Cai, Z.W., Zhang, Y.Z., Borzilleri, R.M. et al. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-S-yloxy)-S-methylpyrrolo[2, 1-fJ[1,2,4]triazin-6-yloxy)propan-2-yl) 2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem 2008, 51(6): 1976-1980.
4. Chen, B.-C, Zhao, R., Sundeen, J.E., Leftheris, K., Hynes, J., Wrobleski, S.T. (Bristol-Myers Squibb Co.). Process for preparing pyrrolotriazine kinase inhibitors. JP 2006516653, US 2004157846, WO 2004072030.
5. Carmeliet, P., Jain, R.K. Anglogenesis in cancer and other diseases. Nature 2000, 407(6801): 249-257
6. Ramanujan, S., Koenig, G.C., Padera, T.P., Stoll, B.R., Jain, R.K. Local imbalance of proangtogenic and antiangiogenic factors: A potential mechanism of focal necrosis and dormancy in tumors. Cancer Res 2000, 60(5): 1442-1448 (Pubitemid 30152019)
7. Kondo, T., Zheng, L., Liu, W., Kurebayashi, J., Asa, S.L., Ezzat, S. Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-octivated protein kinase pathway to modulate thyroid cancer progression. Cancer Res 2007, 67(11): 5461-5470 (Pubitemid 46997287)
8. Hanahan, D., Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86(3): 353-364 (Pubitemid 26272076)
9. Folkman, J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971, 285(21): 1182-1186
10. Ferrara, N., Kerbel, R.S. Angiogenesis as a therapeutic target. Nature 2005, 438(7070): 967-974
11. Cristofanilli, M., Charnsangavej, C, Hortobagyi, G.N. Angiogenesis modulation in cancer research: Novel clinical approaches. Nat Rev Drug Discov 2002, 1(6): 415-426 (Pubitemid 37361484)
12. Ferrara, N., Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr Rev 1997, 18(1): 4-25. (Pubitemid 27076453)
13. Griffioen, A.W., Molema, G. Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000, 52(2): 237-268
14. Kerbel, R., Folkman, J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002, 2(10): 727-739
15. Korpelainen, E.I, Alitalo, K. Signaling angiogenesis and lymphangiogenesis. Curr Opin Cell Biol 1998, 10(2): 159-164
16. Neufeld, G., Cohen, T., Gengrinovitch, S., Poltorak, Z. Vascular endothelial growth factor (VECF) and its receptors. FASEB J 1999, 13(1): 9-22. (Pubitemid 29038270)
17. Kim, K.J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H.S., Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362(6423): 841-844 (Pubitemid 23132159)
18. Masood, R., Cai, J., Zheng, T., Smith, D.L., Naidu, Y, Gill, P.S. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc Natl Acad Sci U S A 1997, 94(3): 979-984 (Pubitemid 27074433)
19. Drevs, J., Hofmann, I., Hugenschmidt, H. et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 2000, 60(17): 4819-4824
20. Fong, T.A., Shawver, L.K., Sun, L. et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999, 59(1): 99-106. (Pubitemid 29062964)
21. Wedge, S.R, Ogilvie, D.J., Dukes, M. et al. AZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002, 62(16): 4645-4655
22. Kerbel, R.S, Yu, J,, Tran, J. et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: Implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001, 20(1-2): 79-86. (Pubitemid 34074682)
23. Miller, K.D., Sweeney, C.J., Sledge, G.W., Jr. The Snark is a Boojum: The continuing problem of drug resistance in the antiangiogenic era. Ann Oncol 2003, 14(1): 20-28
24. Miller, K.D., Sweeney, C.J., Sledge, G.W., Jr. Can tumor angiogenesis be inhibited without resistance? EXS 2005, 94:95-112.
25. Casanovas, O., Hicklin, D.J., Bergers, G., Hanahan, D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8(4): 299-309. (Pubitemid 41443415)
26. Takahashi, J.A., lgarashi, K., Oda, K., Kikuchi, H., Hatanaka, M. Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. J Neurosurg 1992, 76(5): 792-798
27. Folkman, J., Klagsbrun, M. Angiogenic factors. Science 1987, 235(4787): 442-447
28. Dell'Era, P., Belleri, M., Stabile, H., Massrdi, M.L, Ribatti, D., Presta, M. Paracrine and autocrine effects of fibroblast growth factor-4 in endothelial cells. Oncogene 2001, 20(21): 2655-2663 (Pubitemid 32525296)
29. Javerzat, S., Auguste, P., Bikfalvi, A. The role of fibroblast growth factors in vascular development. Trends Mol Med 2002, 8(10): 483-489
30. Giavazzi, R., Giuliani, R., Coltrini, D. et al. Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors. Cancer Res 2001, 61(1): 309-317 (Pubitemid 32095732)
31. Giavazzi, R., Sennino, B., Coltrini, D. et al. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am J Pathol 2003, 162(6): 1913-1926 (Pubitemid 36613049)
32. Tille, J.C., Wood, J., Mandriota, S.J. et al. Vascular endothelial growth factor (VECF) receptor-2 antagonists inhibit VECF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. J Pharmacol Exp Ther 2001, 299(3): 1073-1085 (Pubitemid 33104979)
33. Nissen, L.J., Cao, R., Hedlund, E.M. et al. Angiogenic factors FCF2 and PDCGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest 2007, 117(10): 2766-2777 (Pubitemid 47529608)
34. Mancuso, M.R., Davis, R., Norberg, S.M. et al. Rapid vascular regrowth in tumors after reversal of VECF inhibition. J Clin Invest 2006, 116(10): 2610-21.
35. Grose, R., Fantl, V., Werner, S. et al. The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development. EMBO J 2007, 26(5): 1268-1278 (Pubitemid 46398706)
36. World Health Organization. The global burden of disease. 2004 update. World Health Organization Web site. http://www.who.int/healthinfo/global-burden- disease/GBD-report-2004updateJull.pdf. Accessed September 23, 2009.
37. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Thun, M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4): 225-249
38. Sun, F.X., Tang, Z.Y., Lui, K.D., Ye, S.L., Xue, Q., Gao, D.M., Ma, Z.C. Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. lnt J Cancer 1996, 66(2): 239-243
39. Miura, H., Miyazaki, T., Kuroda, M. et al. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol 1997, 27(5): 854-861 (Pubitemid 27454829)
40. Torimura, T., Sata, M., Ueno, T. et al. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 1998, 29(9): 986-991 (Pubitemid 28422048)
41. Poon, R.T., Ng, I.O, Lau, C., Yu, W.C., Fan, S.T., Wong, J. Correlation of sewm basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg 2001, 182(3): 298-304.
42. Suzuki, K., Hayashi, N., Miyamoto, Y. et al. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res 1996, 56(13): 3004-3009 (Pubitemid 26199745)
43. Jin-no, K., Tanimizu, M., Hyodo, I. et al. Circulating platelet-derived endothelial cell growth factor increases in hepatocellular carcinoma patients. Cancer 1998, 82(7): 1260-1267 (Pubitemid 28155387)
44. Yamaguchi, R., Yano, H., lemura, A., Ogasawara, S., Haramaki, M., Kojiro, M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998, 28(1): 68-77.
45. An, F.Q., Matsuda, M., Fujii, H., Matsumoto, Y. Expression of vascular endothelial growth factor in surgical specimens of hepatocellular carcinoma. J Cancer Res Clin Oncol 2000, 126(3): 153-160 (Pubitemid 30140215)
46. Li, X., Tang, Z., Zhou, G. [Expression of vascular endothelial growth factor correlates with invasion and metastasis of hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi 1998, 20(1): 12-14
47. Jinno, K., Tanimizu, M., Hyodo, I. et al. Circulating vascular endothelial growth factor (VECF) is a possible tumor maricer for metastasis in human hepatocellular carcinoma. J Gastroenterol 1998, 33(3): 376-382 (Pubitemid 28263653)
48. Moon, W.S., Rhyu, K.H., Kang, M.J. et al. Overexpression of VECF and angiopoietin 2: A key to high vascularity of hepatocellular carcinoma? Mod Pathol 2003, 16(6): 552-557
49. Mise, M., Arii, S., Higashituji, H. et al. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 1996, 23(3): 455-464 (Pubitemid 26087158)
50. Ingber, D. Extracellular matrix and cell shape: Potential control points for inhibition of angiogenesis. J Cell Biochem 1991, 47(3): 236-241
51. El Assal, O.N., Yamanoi, A., Ono, T., Kohno, H., Nagasue, N. The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin Cancer Res 2001, 7(5): 1299-1305 (Pubitemid 32708684)
52. Yoshiji, H., Kuriyama, S., Yoshii, J. et al. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology 2002, 35(4): 834-842 (Pubitemid 34258377)
53. Kin, M., Sata, M., Ueno, T. et al. Basic fibroblast growth factor regulates proliferation and motility of human hepatoma cells by an autocrine mechanism. J Hepatol 1997, 27(4): 677-687 (Pubitemid 27448752)
54. Bhide, R.S., Fargnoli, J. Discovery of brivanib alaninate: A dual vascular endothelial growth factor and fibroblast growth factor receptor inhibitor. In: Kinase Inhibitor Drugs. Li, R., Stafford, J.A. (Eds.). John Wiley & Sons, Incorporated: 2009.
55. Fargnoli, J., Bhide, R., Lombardo, L. et al. Preclinical studies of BMS-582664, an alanine prodrug of BMS-540215, a potent, dual inhibitor of VECFR-2 and FCFR-1 kinases. Proc Am Assoc Cancer Res 2005, 46:713.
56. Bhide, R.S., Lombardo, L.J., Hunt, J.T. et al. The antiangiogenic activity in xenograft models of brivanib alaninate, a dual inhibitor of VECFR-2 and FCFR-1 kinases. Mol Cancer Ther 2010, In press
57. Huynh, H., Chow, P.K., Palanisamy, N. et al. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Hepatol 2008, 49(1): 52-60.
58. Huynh, H., Soo, K.C., Chow, P.K., Panasci, L., Tran, E. Xenografts of human hepatocellular carcinoma: A useful model for testing drugs. Clin Cancer Res 2006, 12(14 Pt 1): 4306-4314
59. Huynh, H., Ngo, V.C., Fargnoli, J. et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 2008, 14: 6146-6153
60. Ansiaux, R., Baudelet, C., Jordan, B.F. et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 2005, 11(2 Pt 1): 743-750 (Pubitemid 40116903)
61. Segers, J., Di, F., V., Ansiaux, R., Martinive, P., Feron, O., Wallemacq, P., Gallez, B. Potentiation of cyclophosphamide chemotherapy using the antiangiogenic drug thalidomide: Importance of optimal scheduling to exploit the 'normalization' window of the tumor vasculature. Cancer Lett 2006, 244(1): 129-135
62. Winkler, F., Kozin, S.V., Tong, R.T. et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6(6): 553-563 (Pubitemid 40017699)
63. Jain, R.K., Safabakhsh, N., Sckell, A. et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor. Proc Natl Acad Sci U S A 1998, 95(18): 10820-10825 (Pubitemid 28413152)
64. Tong, R.T., Boucher, Y., Kozin, S.V., Winkler, F., Hicklin, D.J., Jain, R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004, 64(11): 3731-3736 (Pubitemid 38697278)
65. Marathe, P.H., Kamath, A.V., Zhang, Y., D'Arienzo, C., Bhide, R., Fargnoli, J. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VECFR2 inhibitor and its alanine ester prodrug brivanib alaninate. Cancer Chemother Pharmacol 2009, 65(1): 55-66.
66. Malone, H., Pictroski, C., Kukral, D., Fargnoli, J., Galbraith, S., Krishnan, B.S. Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) tumor microcirculation studies in tumor bearing mice treated with VEGFR inhibitor BMS-582664. Proc Am Assoc Cancer Res 2005, 46:911-912
67. Rosen, L.S., Wilding, G., Sweeney, C.J. et al. Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664, a VECFR/FCFR inhibitor in patients with advanced/metastatic solid tumors. J Clin Oncol 2006, 24(18S): [Abstract 3051].
68. Jonker, D., Rosen, L.S., Sawyer, M. et al. A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in patients (pts) with advanced/metastatic solid tumors: Safety, pharmacokinetic (PK), and pharmacodynamic (PD) findings. J Clin Oncol 2007, 25(18S): 152 S [Abstract 3559].
69. Ganapathi, R., Mekhail, T., Wu, C. et al. Moss balance, pharmacokinetics, and metabolism of [14C] brivanib in subjects with advanced or metastatic solid tumors. ASCO General Meeting (May 29-June 2, Orlando) 2009, Abst 3566.
70. Wang, X., Syed, S., Masson, E., Walters, I., Amit, A., Zhang, L. Characterization of brivanib pharmacokinetics in Asian and non-Asian subjects with advanced or metastatic solid tumors. Asian Pacific Association for the Study of the Liver (APASL) (April 13-16, Hong Kong) 2009, Abst PE256.
71. El-Khoueiry, A., Posey, J., Wood, T. et al. Effects of hepatic impairment on the pharmacokinetics of brivanib in a phase 1, open-label, multidose study in patients with hepatocellular carcinoma and other solid tumors. The 44th Annual Meeting of the European Association for the Study of the Liver (EASL) (April 22-26, Copenhagen) 2009.
72. Llovet, J.M., Di Bisceglie, A.M., Bruix, J. et at. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008, 100(10): 698-711.
73. Yao, D.F., Dong, Z.Z., Yao, M. Specific molecular markers in hepatocellular carcinoma. Hepatobiliary Pancreat Dis lnt 2007, 6(3): 241-247 (Pubitemid 46925243)
74. Chan, S.L., Mo, F.K., Johnson, P.J. et at. New utility of an old marker: Serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 2009, 27(3): 446-452
75. Vora, S.R., Zheng, H., Stadler, Z.K., Fuchs, C.S., Zhu, A.X. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist 2009, 14(7): 717-725
76. Kalluri, R. Basement membranes: Structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003, 3(6): 422-433 (Pubitemid 37328846)
77. Ayers, M., Fargnoli, J., Lewin, A., Wu, Q., Platero, J.S. Discovery and validation ofbiomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist. Cancer Res 2007, 67(14): 6899-6906
78. Nuyten, D., Mokliatchouk, O., Goss, G. et al. Changes in plasma pharmacodynamic (PD) biomarkers, and association of these biomarkers and FGF2 levels in tumors with response and PFS with brivanib, an orally available dual inhibitor of VEGFR and FGFR. 11th International Symposium on Anti-Angiogenic Agents (ISAAA) (Feb 5-7, San Diego) 2009.
79. Garrett, C., Siu, L., El-Khoueiry, A. et al. A phase I study of brivanib alaninate (BMS-582664), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full dose cetuximab (BC) in patients (pts) with advanced gastrointestinal malignancies (ACM) who failed prior therapy. J Clin Oncol 2008, 26(May supplement): Abst 4111.
80. Ayers, M., Awad, M., Malone, D. et al. Association of K-ras status with efficacy end points from a phase 1/2 study of brivanib in combination with cetuximab in patients with advanced or metastatic colorectal cancer (CRC). American Society of Clinical Oncology Gastrointestinal Cancers (ASCOGl) (Jan 15-17, San Francisco) 2009, Abst 375.
81. Pereg, D., Lishner, M. Bevactzumab treatment for cancer patients with cardiovascular disease: A double edged sword? Bur Heart J 2008, 29(19): 2325-2326
82. Raoul, J.-L., Finn, R., Kang, Y.K. et al. An open-label phase II study of first-and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC). ASCO General Meeting (May 29-June 2, Orlando) 2009, Abst 4577.
83. Park, J.W., Harris, R., Barrett, B., Baudelet, C., Walters, I. A subanalysis of Asian and non-Asian patients with hepatocellular carcinoma (HCC) treated in a phase 2 safety and efficacy study of brivanib as first-line therapy. Asian Pacific Association for the Study of the Liver (APASL) (April 13-16, Hong Kong) 2009, Abst PE256.
84. Sherman, M., Chen, M., Chen, P.-J. et al. HCC Bridge Study. BRIDGE to better outcomes in hepatocellular carcinoma. 3rd International Liver Cancer Association (ILCA) Meeting (Sept 4-6, Milan) 2009, Abst P-177.